Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Mallinckrodt
Dow
McKesson

Last Updated: February 7, 2023

NASONEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Nasonex, and what generic alternatives are available?

Nasonex is a drug marketed by Organon Llc and Perrigo Pharma Intl and is included in two NDAs.

The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nasonex

A generic version of NASONEX was approved as mometasone furoate by PADAGIS US on March 18th, 2002.

  Try it Free

Paragraph IV (Patent) Challenges for NASONEX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NASONEX Nasal Spray mometasone furoate 50 mcg/ Spray 020762 1 2009-08-07

US Patents and Regulatory Information for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Perrigo Pharma Intl NASONEX 24HR ALLERGY mometasone furoate SPRAY, METERED;NASAL 215712-001 Mar 17, 2022 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 See Plans and Pricing See Plans and Pricing
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 See Plans and Pricing See Plans and Pricing
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 See Plans and Pricing See Plans and Pricing
Organon Llc NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NASONEX

See the table below for patents covering NASONEX around the world.

Country Patent Number Title Estimated Expiration
New Zealand 199600 17-(HETEROCYCLIC CARBOXYLATE)-SUBSTITUTED STEROIDS See Plans and Pricing
Norway 820263 See Plans and Pricing
European Patent Office 0740550 UTILISATION DU FUROATE DE MOMETASONE POUR LE TRAITEMENT DES AFFECTIONS PULMONAIRES ET DES VOIES RESPIRATOIRES (USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASES) See Plans and Pricing
Denmark 0740550 See Plans and Pricing
Bulgaria 60755 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NASONEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0548114 SPC/GB97/064 United Kingdom See Plans and Pricing PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
0112669 96C0002 Belgium See Plans and Pricing PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
3043773 2022C/520 Belgium See Plans and Pricing PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
3043773 132021000000191 Italy See Plans and Pricing PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
0057401 94C0004 Belgium See Plans and Pricing PRODUCT NAME: MOMETASONI FUROAS; NAT REG.: 304 S 133 F 7 19930813; FIRST REG.: GR 10682/89 19900622
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Moodys
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.